Search

Displaying results 6541 - 6550 of 8171 in total
  1. Drug

    Abetimus

    go.drugbank.com/drugs/DB06662
    Investigational

    Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

  2. Drug

    Pelitinib

    go.drugbank.com/drugs/DB05524
    Investigational

    Pelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.

  3. Drug

    Asvasiran

    go.drugbank.com/drugs/DB05638
    Investigational

    Asvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.

  4. Drug

    Staurosporine

    go.drugbank.com/drugs/DB02010
    Experimental

    An indolocarbazole that is a potent protein kinase C inhibitor which enhances cAMP-mediated responses in human neuroblastoma cells. (Biochem Biophys Res Commun 1995;214(3):1114-20)

    Categories: P-glycoprotein inhibitors
  5. Drug

    N-acetyl-beta-neuraminic acid

    go.drugbank.com/drugs/DB04265
    Experimental

    An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518)

    Synonyms: N-acetyl-beta-D-neuraminic acid
  6. Drug

    XmAb24306

    go.drugbank.com/drugs/DB17526
    Investigational

    XmAb24306 is an investigational cancer immunotherapy. It is a heterodimeric interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) complex fused to a bispecific Fc domain.

  7. Drug

    MK-8189

    go.drugbank.com/drugs/DB19153
    Investigational

    MK-8189 is under investigation in clinical trial NCT04624243 (Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)).

  8. Drug

    Dubermatinib

    go.drugbank.com/drugs/DB15187
    Investigational

    Dubermatinib is under investigation in clinical trial NCT03572634 (Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL).

  9. Drug

    AGT-182

    go.drugbank.com/drugs/DB17630
    Investigational

    AGT-182 is an investigational enzyme replacement therapy engineered by the fusion of the iduronate-2-sulfatase (IDS) enzyme and a human insulin receptor monoclonal antibody.

  10. Drug

    CD68-ET3-LV

    go.drugbank.com/drugs/DB32864
    Investigational

    CD68-ET3-LV is an autologous gene therapy consisting of CD34+ hematopoietic stem and progenitor cells transduced ex-vivo with the CD68-ET3-LV lentiviral vector.